The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis
Abstract
The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gut hormones that act via the enteroinsular axis to potentiate insulin secretion from the pancreas in a glucose-dependent manner. Both GLP-1 receptor and GIP receptor knockout mice ( GLP-1R −/− and GIPR −/− , respectively) have been generated to investigate the physiological importance of this axis. Although reduced GIP action is a component of type 2 diabetes, GIPR-deficient mice exhibit only moderately impaired glucose tolerance. The present study was directed at investigating possible compensatory mechanisms that take place within the enteroinsular axis in the absence of GIP action. Although serum total GLP-1 levels in GIPR knockout mice were unaltered, insulin responses to GLP-1 from pancreas perfusions and static islet incubations were significantly greater (40–60%) in GIPR −/− than in wild-type ( GIPR +/+ ) mice. Furthermore, GLP-1-induced cAMP production was also elevated twofold in the islets of the knockout animals. Pancreatic insulin content and gene expression were reduced in GIPR −/− mice compared with GIPR +/+ mice. Paradoxically, immunocytochemical studies showed a significant increase in β-cell area in the GIPR-null mice but with less intense staining for insulin. In conclusion, GIPR −/− mice exhibit altered islet structure and topography and increased islet sensitivity to GLP-1 despite a decrease in pancreatic insulin content and gene expression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in vitro potency and preclinical efficacy data directly assessing these relationships is lacking and confounded by the apparent reduction in potency of GIPR agonists in rodents [61] and the compensatory sensitization of incretin receptors in genetic knockout mouse lines [62,63].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [62]
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Quantitative RT-PCR: Pitfalls and Potential
Freeman, W. M., Walker, S. J., & Vrana, K. E. (1999) · BioTechniques · doi:10.2144/99261rv01 · Cited by 1,149
Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 834
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01043.x · DOI
- Trumper A, 2001, Mol Endocrinol, 15, 1559
- Willms B, 1996, J Clin Endocrinol Metab, 81, 327
Cited by
Sorted by citations
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“221,222 Activation of Akt stimulates β -cell proliferation, reduces apoptosis, and enhances insulin secretion by regulating downstream effector molecules like Forkhead box protein O1 (FoxO1) and the glucose transporter type 2 (GLUT2).”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 537
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Metadata
- Authors
- Pamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., & Pederson, R. A.
- Affiliations
- University of British Columbia (CA)
- Kyoto University (JP)
- ORCID
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2003-05-01
- Volume
- 284
- Issue
- 5
- Pages
- E931-E939
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2098266516
- Cited by
- 126
- References
- 47
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 3 · 2019: 7 · 2018: 7 · 2017: 4 · 2016: 7 · 2015: 7 · 2014: 2 · 2013: 2 · 2012: 4
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucose-dependent insulinotropic polypeptide, enteroinsular axis, glucagon-like peptide-1, GLP-1 receptor, pancreatic beta cells, insulin secretion, compensatory mechanisms, cAMP signaling, type 2 diabetes, incretins
- MeSH terms
- Adaptation, Physiological, Cyclic AMP, Animals, Arginine, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Glucose Tolerance Test, Immunohistochemistry, Insulin, Intestines, Intracellular Membranes, Islets of Langerhans, Mice, Inbred C57BL, Pancreas, Peptide Fragments, Protein Precursors, Receptors, Gastrointestinal Hormone, RNA, Messenger, Mice, Knockout, Mice, Glucagon-Like Peptide 1, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
